Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • inflammation

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn

    The companies are aiming to develop MGDs for targets across oncology and immunology

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

    The deal gives the company access to a range of central nervous system disorder drugs

    - PMLiVE

    Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

    The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

    - PMLiVE

    AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

    The deal includes a candidate in phase 1 development for Alzheimer's disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links